Clinical trials: Depressive Symptoms
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Depressive Disorder, Major
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally…
- Trial name
- SUVN-911 (NCT03155503)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety and tolerability of agomelatine 25 mg or 50 mg per day and will compare agomelatine and paroxetine tolerability.
- Trial name
- NCT00463242
- Testing
- Agomelatine, paroxetine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 501 people
- Sponsor
- Novartis
Chronic Kidney Disease Stage V, Hemodialysis
Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients
This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous [IV]) is administered in Venezuelan patients on hemodialysis who are at risk of developing…
- Trial name
- NCT01758289
- Where
- 8 sites in Venezuela
- Volunteers
- 105 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Bipolar Disorder, Schizophrenia
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®).
- Trial name
- NCT01495741
- Volunteers
- 42 people
- Sponsor
- Organon and Co
Major Depressive Disorder
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in…
- Trial name
- NCT00531622
- Testing
- saredutant (SR48968), escitalopram
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Major Depressive Disorder, Depression
Individual Patient Esmethadone (REL-1017) Expanded Access Program
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other…
- Trial name
- NCT06009003
- Testing
- REL-1017
- Sponsor
- Relmada Therapeutics, Inc.
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
Depression, Cognition
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder
- Trial name
- NCT00062673
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
- Trial name
- NCT05593029
- Testing
- SEP-363856
- Where
- 77 sites in United States, Bulgaria and 5 more
- Volunteers
- 929 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Depressive Disorder, Depression
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Orion (NCT01360866)
- Testing
- OPC-34712, Escitalopram, Fluoxetine
- Where
- 142 sites in United States, Canada and 9 more
- Volunteers
- 2,944 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Syndrome, Anxiety
Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients
In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome.
- Trial name
- NCT00247429
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250601
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Sanofi
Major Depressive Disorder (MDD)
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
- Trial name
- NCT01683019
- Testing
- NeoSync EEG Synchronization Therapy
- Where
- 2 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder
Major Depressive Disorder With Mixed Features - Extension
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features…
- Trial name
- RESOLVE3 (NCT01423253)
- Testing
- Lurasidone
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00256113
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 467 people
- Sponsor
- Sanofi